BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 31866097)

  • 21. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials.
    Taieb J; Sinicrope FA; Pederson L; Lonardi S; Alberts SR; George TJ; Yothers G; Van Cutsem E; Saltz L; Ogino S; Kerr R; Yoshino T; Goldberg RM; André T; Laurent-Puig P; Shi Q
    Ann Oncol; 2023 Nov; 34(11):1025-1034. PubMed ID: 37619846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
    Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
    Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
    BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of BRAF mutation alone and in combination with microsatellite instability in stage III colon cancer.
    Chouhan H; Sammour T; L Thomas M; W Moore J
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):69-74. PubMed ID: 30421554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based study.
    Wish TA; Hyde AJ; Parfrey PS; Green JS; Younghusband HB; Simms MI; Fontaine DG; Dicks EL; Stuckless SN; Gallinger S; McLaughlin JR; Woods MO; Green RC
    Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1831-9. PubMed ID: 20570909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
    Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
    J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular heterogeneity and prognostic implications of synchronous advanced colorectal neoplasia.
    Malesci A; Basso G; Bianchi P; Fini L; Grizzi F; Celesti G; Di Caro G; Delconte G; Dattola F; Repici A; Roncalli M; Montorsi M; Laghi L
    Br J Cancer; 2014 Mar; 110(5):1228-35. PubMed ID: 24434431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS.
    Alwers E; Bläker H; Walter V; Jansen L; Kloor M; Arnold A; Sieber-Frank J; Herpel E; Tagscherer KE; Roth W; Chang-Claude J; Brenner H; Hoffmeister M
    BMC Cancer; 2019 Jul; 19(1):681. PubMed ID: 31296182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.
    Lochhead P; Kuchiba A; Imamura Y; Liao X; Yamauchi M; Nishihara R; Qian ZR; Morikawa T; Shen J; Meyerhardt JA; Fuchs CS; Ogino S
    J Natl Cancer Inst; 2013 Aug; 105(15):1151-6. PubMed ID: 23878352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
    Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
    Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
    Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
    Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.
    Tran B; Kopetz S; Tie J; Gibbs P; Jiang ZQ; Lieu CH; Agarwal A; Maru DM; Sieber O; Desai J
    Cancer; 2011 Oct; 117(20):4623-32. PubMed ID: 21456008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
    Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
    Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
    Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
    J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular profiling of the colon cancer in South-Eastern Romania: Results from the MERCUR study.
    Popescu RC; Tocia C; Brînzan C; Cozaru GC; Deacu M; Dumitru A; Leopa N; Mitroi AF; Nicolau A; Dumitru E
    Medicine (Baltimore); 2021 Jan; 100(1):e24062. PubMed ID: 33429770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation and identification of factors related to
    Lin L; Chen GY; Xu CW; Wang HY; Wu YF; Fang MY
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C191-C198. PubMed ID: 28230016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
    Tie J; Gibbs P; Lipton L; Christie M; Jorissen RN; Burgess AW; Croxford M; Jones I; Langland R; Kosmider S; McKay D; Bollag G; Nolop K; Sieber OM; Desai J
    Int J Cancer; 2011 May; 128(9):2075-84. PubMed ID: 20635392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Marine ω-3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability.
    Song M; Nishihara R; Wu K; Qian ZR; Kim SA; Sukawa Y; Mima K; Inamura K; Masuda A; Yang J; Fuchs CS; Giovannucci EL; Ogino S; Chan AT
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25810492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers.
    Bond CE; Umapathy A; Ramsnes I; Greco SA; Zhen Zhao Z; Mallitt KA; Buttenshaw RL; Montgomery GW; Leggett BA; Whitehall VL
    Int J Cancer; 2012 Apr; 130(7):1567-76. PubMed ID: 21557216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes.
    Amitay EL; Carr PR; Jansen L; Walter V; Roth W; Herpel E; Kloor M; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
    J Natl Cancer Inst; 2019 May; 111(5):475-483. PubMed ID: 30388256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.